Drug industry demand for chemical intermediates and development projects has rebounded significantly in the last 12 months according to UK group Endeavour Specialty Chemicals.
PPD signs clinical imaging and formulation development collaborations, reorganises reporting units and cites “improved performance in emerging markets” and spending controls as key to third quarter gains.
PPD is collaborating with the Himalayan Institute and Hospital Trust (HIHT University) to form a large investigator site and expand its network of investigators in Northern India.
Indian CRAs need knowledge of ethics, clinical trial execution and general topics, such as the drug development process, according to a survey into training needs.
The WHO is today initiating a pilot prequalification programme for selected APIs used in drugs for HIV and related diseases, antimalarials and anti-tuberculosis medications.
Revision to FDA guidance on adverse event reporting is a positive step and forms part of a welcome increased focus on safety, says the CEO of Prism Ideas.
Eli Lilly has unveiled plans to close its Singapore R&D centre by the end of the year and relocate discovery operations to its global headquarters in the US.
Southern Research Institute is acquiring BioCryst Pharmaceuticals’ bioanalytical laboratory assets and personnel in a move towards expanding its bioanalytical service offerings.
Prosonix expects high demand for innovative particle processing technologies in the $24bn (€17bn) a-year respiratory pharmaceuticals market over the next few years.
A week of global anti-counterfeiting law enforcement coordinated by Interpol led to the shutdown of 290 websites, seizure of 11,000 packages and confiscation of 1m pills.
SGS Life Sciences will roll out new biologics testing capabilities across its network in bid to be the world’s number one contract biopharmaceuticals testing laboratory by 2014.
A strategic partnership between New England IRB (NEIRB) and Veritas IRB of Montreal will see their clients following a common protocol review for studies they conduct throughout the US and Canada.
Charles River Laboratories (CRL) has added two new exclusive knockout rats to its preclinical development offering in deal with Transposagen Biopharmaceuticals.
The FDA is to collaborate with the WHO to build a global surveillance and monitoring system for combating falsified medicines and breaches of the supply chain.
IMS Health predicts that global drug sales will increase 5 to 7 per cent next year, driven by development of innovative pharmaceuticals and growth of emerging markets.
Easily translatable and adaptable simplified clinical research ethic training guidelines have been created to support field workers in low-resource settings.
Oracle Health Sciences has strengthened its clinical trial analytics offering to reduce start up times and offer greater insight into screening, recruitment and retention.
Guy Villax, board member of the EFCG, talks falsified APIs, EU efforts to tackle the issue, and the presence of gangsters in the pharma industry in an in-PharmaTechnologist video interview.
Wipro Technologies has introduced Rapid Trials to provide clients with a data collection platform that can be deployed quickly and with minimal infrastructure investment.
China leads the field in 'potential future' API suppliers, positioning it to become a dominant force as these companies develop, Thomson Reuters said at CPhI 2010.
Parexel opens its third office in Japan to address rising demands for clinical development and regulation services, and to supplement the capabilities of its Tokyo office which opened in 1997.
BioClinica shareholder Nicusa Capital is calling for the resignation of CEO Mark Weinstein, CFO Ted Kaminer and Chairman David Nowiki, after describing the firm’s corporate strategy as “defective.”
Adoption of electronic submission by regulators around the world is good news for drugmakers’ efforts to access emerging markets says industry expert Kate Wilber.
Covance has added a 40,000 sq ft biotech laboratory to its site in Indiana, US site to support its relationship with Eli Lilly and boost capacity outside Europe.
From 2005 to 2009 61 per cent of US NIH registered trials included at least one study site outside North America. Outsourcing-Pharma presents this, the 2009 downturn in US trials and other data as an interactive visualisation.